TY - JOUR
T1 - Influence of induction chemotherapy in trimodality therapy-eligible oesophageal cancer patients
T2 - Secondary analysis of a randomised trial
AU - Shimodaira, Yusuke
AU - Slack, Rebecca S.
AU - Harada, Kazuto
AU - Chen, Hsiang Chun
AU - Sagebiel, Tara
AU - Bhutani, Manoop S.
AU - Lee, Jeffrey H.
AU - Weston, Brian
AU - Elimova, Elena
AU - Lin, Quan
AU - Amlashi, Fatemeh G.
AU - Mizrak Kaya, Dilsa
AU - Blum, Mariela A.
AU - Roth, Jack A.
AU - Swisher, Stephen G.
AU - Skinner, Heath D.
AU - Hofstetter, Wayne L.
AU - Rogers, Jane E.
AU - Mares, Jaennette
AU - Thomas, Irene
AU - Maru, Dipen M.
AU - Komaki, Ritsuko
AU - Walsh, Garrett
AU - Ajani, Jaffer A.
N1 - Funding Information:
The study is supported by multidisciplinary grants from MD Anderson. It is also supported in part by National Cancer Institute awards CA138671, CA172741, CA150334 (to J.A.A.), and P30CA016672 (the MD Anderson Biostatistics Resource Group). Y.S. was awarded a scholarship from the St. Luke’s Life Science Institute.
PY - 2018/2/6
Y1 - 2018/2/6
N2 - Background:A randomised phase 2 trial of trimodality with or without induction chemotherapy (IC) in oesophageal cancer (EC) patients showed no advantage in overall survival (OS) or pathologic complete response rate. To identify subsets that might benefit from IC, a secondary analysis was done.Methods:The trial had accrued 126 patients (NCT 00525915). Recursive partitioning and proportional hazards regression with interactions were performed.Results:The median follow-up of surviving patients was 6.7 years and the median OS duration was 3.8 years (95% confidence interval (CI), 2.6-5.8 years). OS was associated with tumour length (P=0.03), cT (P=0.02), cN (P=0.04), clinical stage (P=0.01), and tumour grade (P<0.001). The effect of IC differed according to tumour grade. Among patients with well or moderately differentiated (WMD) ECs (n=59), the 5-year survival rate was 74% with IC and 50% without IC, P=0.001. IC had no effect on OS of patients with poorly differentiated (PD) ECs (31% and 28%, respectively; interaction, P=0.04; IC, P=0.03). In the multivariate reduced model, WMD with IC was an independent prognosticator for better OS (HR=0.41, 95% CI, 0.25-0.67; P=<0.001). The following four EC phenotypes emerged for OS: (1) very high risk (PD, cN2/N3), (2) high risk (PD, cN0/N1, stage cIII), (3) moderate risk (PD, cN0/N1, stage cI/II or WMD without IC), and (4) low risk (WMD with IC). The 5-year survival rates were 11%, 27%, 48%, and 74%, respectively (P<0.001).Conclusions:Our data show that IC significantly prolonged OS of WMD EC patients who undergo trimodality; prospective evaluation is needed.
AB - Background:A randomised phase 2 trial of trimodality with or without induction chemotherapy (IC) in oesophageal cancer (EC) patients showed no advantage in overall survival (OS) or pathologic complete response rate. To identify subsets that might benefit from IC, a secondary analysis was done.Methods:The trial had accrued 126 patients (NCT 00525915). Recursive partitioning and proportional hazards regression with interactions were performed.Results:The median follow-up of surviving patients was 6.7 years and the median OS duration was 3.8 years (95% confidence interval (CI), 2.6-5.8 years). OS was associated with tumour length (P=0.03), cT (P=0.02), cN (P=0.04), clinical stage (P=0.01), and tumour grade (P<0.001). The effect of IC differed according to tumour grade. Among patients with well or moderately differentiated (WMD) ECs (n=59), the 5-year survival rate was 74% with IC and 50% without IC, P=0.001. IC had no effect on OS of patients with poorly differentiated (PD) ECs (31% and 28%, respectively; interaction, P=0.04; IC, P=0.03). In the multivariate reduced model, WMD with IC was an independent prognosticator for better OS (HR=0.41, 95% CI, 0.25-0.67; P=<0.001). The following four EC phenotypes emerged for OS: (1) very high risk (PD, cN2/N3), (2) high risk (PD, cN0/N1, stage cIII), (3) moderate risk (PD, cN0/N1, stage cI/II or WMD without IC), and (4) low risk (WMD with IC). The 5-year survival rates were 11%, 27%, 48%, and 74%, respectively (P<0.001).Conclusions:Our data show that IC significantly prolonged OS of WMD EC patients who undergo trimodality; prospective evaluation is needed.
UR - http://www.scopus.com/inward/record.url?scp=85041661800&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85041661800&partnerID=8YFLogxK
U2 - 10.1038/bjc.2017.423
DO - 10.1038/bjc.2017.423
M3 - Article
C2 - 29235564
AN - SCOPUS:85041661800
SN - 0007-0920
VL - 118
SP - 331
EP - 337
JO - British journal of cancer
JF - British journal of cancer
IS - 3
ER -